Attached files
| file | filename |
|---|---|
| EX-32.1 - EXHIBIT 32.1 - Brooklyn ImmunoTherapeutics, Inc. | brhc10027925_ex32-1.htm |
| EX-31.2 - EXHIBIT 31.2 - Brooklyn ImmunoTherapeutics, Inc. | brhc10027925_ex31-2.htm |
| EX-31.1 - EXHIBIT 31.1 - Brooklyn ImmunoTherapeutics, Inc. | brhc10027925_ex31-1.htm |
| 10-Q - 10-Q - Brooklyn ImmunoTherapeutics, Inc. | brhc10027925_10q.htm |
Exhibit 32.2
CERTIFICATION PURSUANT TO 18 U.S.C. 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Brooklyn ImmunoTherapeutics, Inc. for the quarterly period ended June 30, 2021, as filed with the Securities and
Exchange Commission on the date hereof (the “Report”), the undersigned certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to his knowledge on the date hereof:
1. the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Brooklyn ImmunoTherapeutics, Inc.
for the period presented therein.
|
Date: August 13, 2021
|
/s/ Sandra Gurrola
|
|
|
Sandra Gurrola
|
|
|
Vice President of Finance
|
|
|
(Principal Financial Officer)
|
The foregoing certification is being furnished solely pursuant to 18 U.S.C. § 1350 and is not being filed as part of the Report or as a separate
disclosure document.